Key Considerations in Biosimilars Development

被引：0
|
作者：
Donninger, Raymond
Bower, Joe
Kaiser, Raymond
Estdale, Sian
Carlsen, John
机构：
来源：
BIOPHARM INTERNATIONAL | 2012年 / 25卷 / 10期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：37 / 39
页数：3
相关论文
共 50 条
  • [41] Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists
    White, Shannon
    Morrow, Ryan
    Pan, Ingrid
    de Zoeten, Edwin F.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 76 (06): : 701 - 703
  • [42] Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations
    Gulacsi, Laszlo
    Pentek, Marta
    Rencz, Fanni
    Brodszky, Valentin
    Baji, Petra
    Vegh, Zsuzsanna
    Gecse, Krisztina B.
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    Lakatos, Peter L.
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (02) : 259 - 269
  • [43] Biosimilars of Biological Drug TherapiesRegulatory, Clinical and Commercial Considerations
    George Dranitsaris
    Eitan Amir
    Kristine Dorward
    Drugs, 2011, 71 : 1527 - 1536
  • [44] EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars
    Begoña Calvo
    Leyre Zuñiga
    Drug Safety, 2014, 37 : 9 - 18
  • [45] Regulatory considerations in biosimilars: Middle East and Africa regions
    Rathore, Anurag S.
    Bhargava, Ankita
    PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY, 2021, 51 (08): : 731 - 737
  • [46] EU's New Pharmacovigilance Legislation: Considerations for Biosimilars
    Calvo, Begona
    Zuniga, Leyre
    DRUG SAFETY, 2014, 37 (01) : 9 - 18
  • [47] The surge in biosimilars: considerations for effective pharmacovigilance and EU regulation
    Calvo, Begona
    Martinez-Gorostiaga, Javier
    Echevarria, Enrique
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2018, 9 (10) : 601 - 608
  • [48] Assessing biosimilars in practice: considerations for the hospital pharmacist to evaluate
    Tredree, Roger
    EJHP PRACTICE, 2009, 15 (03): : 28 - 30
  • [49] Biosimilars 101: considerations for US oncologists in clinical practice
    Camacho, Luis H.
    Frost, Craig P.
    Abella, Esteban
    Morrow, Phuong K.
    Whittaker, Sadie
    CANCER MEDICINE, 2014, 3 (04): : 889 - 899
  • [50] Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
    Dipasquale, Valeria
    Cucinotta, Ugo
    Romano, Claudio
    BIOLOGICS-TARGETS & THERAPY, 2022, 16 : 57 - 66
12345